DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

Information source: University Hospital, Strasbourg, France
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Intervention: pet-scan FDG-F18 (Other)

Phase: Phase 4

Status: Terminated

Sponsored by: University Hospital, Strasbourg, France

Official(s) and/or principal investigator(s):
Jérôme DE SEZE, MD, Principal Investigator, Affiliation: Hôpitaux universitaires de Strasbourg

Summary

To evaluate the diagnosis value of MRI and positon emission tomography (PET) scan for studying macrophagic infiltration and other brain modification in multiple sclerosis (MS) patients treated with Natalizumab (Tysabri).

Clinical Details

Official title: MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).

Secondary outcome: Correlation with relapses.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients diagnosed with MS

- Treatment with Tysabri planned

Exclusion Criteria:

- Allergy to Tysabri or MRI contrast products

- Pregnancy

Locations and Contacts

Service de Médecine Nucléaire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg 67098, France

Service de Neurologie, Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg 37091, France

Service de Radiologie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg 67098, France

Additional Information

Starting date: December 2008
Last updated: November 9, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017